首页> 外文OA文献 >A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

【2h】

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

机译：拉帕替尼+帕唑帕尼与拉帕替尼治疗HER2 +炎性乳腺癌患者的随机II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Massimo Cristofanilli; Stephen R. D. Johnston; Alexey Manikhas; Henry L. Gomez; Oleg Gladkov; Zhimin Shao; Sufia Safina; Kimberly L. Blackwell; Ricardo H. Alvarez; Stephen D. Rubin; Sulabha Ranganathan; Suman Redhu; Maureen E. Trudeau;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. [J] . Kaufman B, Trudeau M, Awada A The lancet oncology . 2009,第6期

机译：II期研究EGF103009中的HER2过表达复发或难治性炎性乳腺癌患者的拉帕替尼单药治疗：扩大结果的HER2 +队列的最终结果和生存率。
2. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J] . Pivot Xavier, Manikhas Alexey, Zurawski Bogdan, Journal of Clinical Oncology . 2015,第14期

机译：CEREBEL（EGF111438）：拉帕替尼加卡培他滨与曲妥珠单抗加卡培他滨对人类表皮生长因子受体2-阳性转移性乳腺癌患者的III期随机，开放标签研究
3. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J] . Pivot Xavier, Manikhas Alexey, Zurawski Bogdan, Journal of Clinical Oncology . 2015,第14期

机译：CEREBEL（EGF111438）：Lapatinib Plus Capecitabine的AII，随机开放标签研究与人体表皮生长因子受体2阳性转移性乳腺癌患者的患者曲据
4. Proteomics Proteomics Reveals Overexpression of the Tyrosine Kinase AXL as a Novel Mechanism of Lapatinib Resistance in Breast Tumor Cells [C] . Roland S. Annan, Therese Collingwood, Francesca Zappacosta, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：蛋白质组学蛋白质组学显示酪氨酸激酶AXL的过表达作为乳腺肿瘤细胞中Lapatinib抗性的新机制
5. Role of Lapatinib and Retinoids In Overcoming Intrinsic Resistance to Hormonal Therapy In Breast Cancer [D] . Gilani, Rabia Afzal 2011

机译：拉帕替尼和类维生素A在克服乳腺癌激素治疗的内在抗性中的作用
6. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer [O] . Massimo Cristofanilli, Stephen R. D. Johnston, Alexey Manikhas, -1

机译：拉帕替尼+帕唑帕尼与拉帕替尼治疗HER2 +炎性乳腺癌患者的随机II期研究
7. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial [O] . Piccart-Gebhart, Martine, Pritchard, Kathleen, McCullough, Ann A.E., 2016

机译：辅助拉帕替尼和曲妥珠单抗治疗早期人类表皮生长因子受体2阳性乳腺癌：结果来自随机III期拉帕替尼和/或曲妥珠单抗治疗优化试验

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅